OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.76 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 9.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 20,133 shares of the biotechnology company’s stock after selling 2,120 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Blueprint Medicines were worth $1,756,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Blueprint Medicines by 1.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,855 shares of the biotechnology company’s stock worth $3,736,000 after purchasing an additional 612 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Blueprint Medicines by 30.8% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 648,660 shares of the biotechnology company’s stock valued at $56,576,000 after buying an additional 152,573 shares during the period. Gotham Asset Management LLC acquired a new position in Blueprint Medicines in the 4th quarter worth $309,000. Graham Capital Management L.P. boosted its position in shares of Blueprint Medicines by 48.8% during the fourth quarter. Graham Capital Management L.P. now owns 25,260 shares of the biotechnology company’s stock worth $2,203,000 after buying an additional 8,283 shares during the period. Finally, Granahan Investment Management LLC boosted its position in Blueprint Medicines by 8.2% during the 4th quarter. Granahan Investment Management LLC now owns 141,890 shares of the biotechnology company’s stock worth $12,376,000 after acquiring an additional 10,744 shares during the last quarter.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the sale, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. This trade represents a 14.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Monday, May 5th. The shares were sold at an average price of $101.75, for a total transaction of $231,379.50. Following the completion of the sale, the chief operating officer now directly owns 66,992 shares of the company’s stock, valued at approximately $6,816,436. The trade was a 3.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,503 shares of company stock worth $1,027,931 over the last three months. 4.21% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Morgan Stanley assumed coverage on shares of Blueprint Medicines in a research note on Thursday, March 20th. They set an “equal weight” rating and a $100.00 price objective for the company. Jefferies Financial Group assumed coverage on Blueprint Medicines in a report on Monday, March 17th. They set a “buy” rating and a $135.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, May 2nd. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, May 2nd. Finally, Scotiabank assumed coverage on Blueprint Medicines in a report on Friday, March 7th. They issued a “sector outperform” rating and a $150.00 price objective for the company. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $126.56.

Blueprint Medicines Stock Down 0.9%

Shares of NASDAQ:BPMC opened at $99.40 on Wednesday. Blueprint Medicines Co. has a 52-week low of $73.04 and a 52-week high of $121.90. The company has a fifty day moving average of $88.91 and a 200-day moving average of $94.05. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. The company has a market capitalization of $6.42 billion, a PE ratio of -92.04 and a beta of 0.83.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.32). The company had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.40 earnings per share. On average, equities analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.